The data from this NALM-6 re-challenge, along with data shown in Fig. 5c, demonstrate that the in vivo anti-tumor activity of ET190L1-AbTCR-T cells extends to CD19+ tumor types that do not express the CD80 and CD86 costimulatory ligands. This evidence concerns the gene CD19 and neoplasm.